Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA:688806)

SHA:688806 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 3, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Debt / Equity Ratio	28.40	6.02	1.05	0.29	0.12
Net Debt / Equity Ratio	11.09	1.56	-0.41	-0.59	-0.66
Net Debt / EBITDA Ratio	-0.63	-0.32	0.32	0.95	1.83
Net Debt / FCF Ratio	-0.57	-0.30	0.41	1.28	1.76
Asset Turnover	-	0.05	0.02	-	-
Inventory Turnover	-	0.38	0.37	-	-
Quick Ratio	1.27	1.33	1.97	5.38	5.78
Current Ratio	1.66	1.63	2.20	5.69	6.19
Return on Equity (ROE)	-	-241.17%	-93.99%	-53.36%	-
Return on Assets (ROA)	-	-38.92%	-33.62%	-27.28%	-
Return on Capital Employed (ROCE)	-100.10%	-113.20%	-79.90%	-53.40%	-36.10%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 3, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Buyback Yield / Dilution	-144.15%	-6.33%	-15.30%	-96.56%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 1, 2026

Data Sources Report a data error